A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.
Anna Maria Di Giacomo(University of Siena), Michele Maio(University of Siena), Riccardo Danielli(University of Siena), Mario Mandalà(University of Perugia), Pier Francesco Ferrucci(MultiMedica), Massimo Guidoboni(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Virginia Ferraresi(Cancer Institute (WIA)), Diego Annesi(University of Siena), Michele Guida(Istituto Tumori Bari), Giorgio Parmiani(Fondazione IRCCS Istituto Nazionale dei Tumori), Pietro Quaglino(Department of Medical Sciences), Paola Queirolo, Cristina Maccalli(Azienda Ospedaliera Universitaria Policlinico "G. Martino"), Diana Giannarelli(Agostino Gemelli University Polyclinic), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Ester Fonsatti(Istituto di Chimica Biomolecolare), Luana Calabrò(University of Siena)
Cited by 8
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k